Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.62 |
| ▸ | VEGFA | P15692 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565865 | 0.88 | EGLN1 (0.57) | EGLN1EGLN3FTOTHRATHRB | |
| SCHEMBL6566125 | 0.86 | EGLN1 (0.52) | EGLN1VEGFAFLT1EGLN3FTO | |
| SCHEMBL964980 | 0.84 | EGLN1 (0.50) | EGLN1VEGFAFLT1PDE3BPDE3A | |
| SCHEMBL1509148 | 0.84 | EGLN1 (0.50) | EGLN1VEGFAFLT1PDE3BPDE3A | |
| SCHEMBL1509109 | 0.83 | EGLN1 (0.64) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL8632084 | 0.83 | EGLN1 (0.59) | EGLN1VEGFAFLT1EGLN3FTO | |
| SCHEMBL967780 | 0.82 | EGLN1 (0.48) | EGLN1EGLN3FTOKDM5BKDM2A | |
| SCHEMBL6567272 | 0.81 | EGLN1 (0.47) | EGLN1VEGFAFLT1PDE3BPDE3A | |
| SCHEMBL6565270 | 0.81 | EGLN1 (0.47) | EGLN1VEGFAFLT1PDE3BPDE3A | |
| SCHEMBL6565422 | 0.81 | EGLN1 (0.55) | EGLN1FTOBBOX1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| EP-1658074-B1 | INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS GAMMA GLOBIN INDUCERS | FIBROGEN INC (US) | 2012-11-07 | — | — | EP | claimed |
| CN-102552261-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-11 | — | — | CN | claimed |
| US-8202834-B2 | Fat regulation | FIBROGEN, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-8124582-B2 | stabilizing alpha subunit of hypoxia inducible factor protein (HIF alpha ), thereby regulating glucose metabolism; preventing or treating hyperglycemia, obesity, hypertension, hyperlipidemia, nephropathy, neuropathy, retinopathy, impaired glucose tolerance, atherosclerosis, and vascular disease | FIBROGEN, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100168152-A1 | Fat regulation | FIBROGEN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-7618940-B2 | Fat regulation | FIBROGEN, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024165507-A1 | USE OF HIF-1Α STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-15 | — | — | WO | disclosed |
| US-11969417-B2 | Topical formulation for use in alopecia | TOMORROWLABS GMBH (AT) | 2024-04-30 | — | — | US | disclosed |
| EP-3917525-B1 | NEW TOPICAL FORMULATION FOR USE IN ALOPECIA | TOMORROWLABS GMBH (AT) | 2024-02-28 | — | — | EP | disclosed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 369/4885FLT1 689/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885VEGFA 2447/4885FLT1 3981/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885VEGFA 177/4885FLT1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.